Core Points - Wuhan Heyuan Biotechnology Co., Ltd. has approved the use of raised funds to replace self-raised funds previously invested in fundraising projects and to cover issuance expenses [2][6] - The total amount of raised funds is approximately RMB 2.6 billion, with a net amount of approximately RMB 2.43 billion after deducting issuance expenses [12][2] - The company plans to use RMB 469.56 million to replace self-raised funds for investment projects and RMB 5.19 million for issuance expenses [4][5] Fundraising Overview - The company issued 89,451,354 shares at a price of RMB 29.06 per share, raising a total of RMB 2,599,456,347.24 [12][2] - After deducting issuance expenses of RMB 169,031,770.68, the net amount raised is RMB 2,430,424,576.56 [12][2] - All raised funds are managed in a special account, with a tripartite supervision agreement in place [3] Investment Project Details - The company has pre-invested RMB 469,556,343.17 in fundraising projects using self-raised funds [4] - The issuance expenses totaled RMB 169,031,770.68, with RMB 5,187,028.30 already paid from self-raised funds [5] Approval Process - The board of directors approved the use of raised funds for replacement at a meeting held on November 21, 2025 [6] - The replacement of funds is compliant with relevant regulations and does not require shareholder approval [6][7] Cash Management Plan - The company plans to manage temporarily idle raised funds (including oversubscription funds) to enhance fund utilization efficiency [9][10] - The cash management will involve purchasing safe, liquid, principal-protected products, with a limit of RMB 2.1 billion [13][10] - The cash management period is valid for 12 months from the board's approval date [13][14] Risk Management - The company will select reputable financial institutions for cash management products and will monitor investment risks closely [19][20] - Independent directors and the audit committee will oversee the use of funds [20][21] Impact on Company Operations - The cash management initiative is designed to improve fund efficiency without affecting ongoing investment projects [23] - The company aims to generate additional returns for itself and its shareholders through this cash management strategy [23][25]

Group 1 - The company will hold its third extraordinary general meeting of shareholders on December 12, 2025, at 15:00 [2][4] - The voting will be conducted through a combination of on-site and online voting systems provided by the Shanghai Stock Exchange [4][6] - Shareholders must register in advance to attend the meeting, with specific documentation required for both individual and corporate shareholders [12][13] Group 2 - The company plans to use RMB 469.56 million of raised funds to replace pre-invested self-raised funds for investment projects and RMB 5.19 million for replacing paid issuance expenses [20][22] - The total amount raised from the initial public offering was approximately RMB 2.6 billion, with a net amount of about RMB 2.43 billion after deducting issuance costs [20][29] - The company has established a special account for managing the raised funds and signed a tripartite supervision agreement with the sponsor and the bank [21][30] Group 3 - The company intends to manage part of its temporarily idle raised funds (including oversubscribed funds) to enhance fund utilization efficiency and increase returns for shareholders [26][39] - The cash management will involve purchasing low-risk, liquid principal-protected products, with a maximum amount of RMB 2.1 billion allocated for this purpose [31][35] - The company will ensure that this cash management does not affect the implementation of investment projects and complies with relevant regulations [33][40] Group 4 - The company plans to purchase Directors and Officers Liability Insurance (D&O Insurance) to mitigate operational risks and protect the interests of directors, senior management, and investors [41][43] - The proposed insurance coverage limit is up to RMB 100 million, with an annual premium not exceeding RMB 400,000 [41][42] Group 5 - The company has approved changes to its registered capital and type, increasing its registered capital from RMB 268.05 million to RMB 357.50 million following its IPO [44][45] - The company will revise its articles of association to reflect these changes and will handle the necessary business registration modifications [44][46]

Core Viewpoint - The company plans to utilize up to 2.1 billion yuan of temporarily idle raised funds for cash management, focusing on safe and liquid principal-protected products [1] Group 1: Cash Management Plan - The company will purchase various financial products, including but not limited to agreement deposits, structured deposits, time deposits, notice deposits, and large-denomination certificates of deposit [1] - The approved cash management plan is valid for 12 months from the date of the board's approval [1] - The company emphasizes that this cash management will not affect the progress of investment projects funded by the raised funds or its normal production and operations [1] Group 2: Use of Proceeds - The income generated from this cash management will be prioritized for supplementing any shortfall in investment projects and for replenishing working capital [1] - The proceeds will be returned to the designated raised funds account as per regulations [1]

Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management, specifically aiming to invest up to 2.1 billion yuan in safe and liquid principal-protected products [1] Group 1: Cash Management Plan - The company will hold its 11th meeting of the 4th Board of Directors on November 21, 2025, to approve the cash management proposal [1] - The proposed investment includes various financial products such as agreed deposits, structured deposits, time deposits, notice deposits, and large certificates of deposit [1] - The approved amount for cash management is valid for 12 months from the date of board approval and can be rolled over within the limit [1] Group 2: Impact on Operations - The company assures that this cash management initiative will not affect the progress of the investment projects funded by the raised capital or its normal production and operations [1] - The income generated from this cash management will be prioritized for supplementing any shortfall in investment projects and for replenishing working capital, with returns directed back to the designated raised funds account as per regulations [1]

国泰海通证券股份有限公司 关于武汉禾元生物科技股份有限公司 使用部分暂时闲置募集资金（含超募资金）进行现金管理的 核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为 武汉禾元生物科技股份有限公司（以下简称"禾元生物"或"公司"）首次公 开发行股票并上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板上市公司自律监管指引第1号——规范运作》《上市公司募集 资金监管规则》《上海证券交易所科创板股票上市规则》等相关法律、法规和 规范性文件的规定，对禾元生物使用部分暂时闲置募集资金（含超募资金）进 行现金管理事项进行了核查，核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意武汉禾元生物科技股份有 限公司首次公开发行股票注册的批复》（证监许可[2025]1468号），公司获准 首次公开发行人民币普通股（A股）股票（以下简称"本次发行"）89,451,354.00 股，每股发行价为人民币29.06元，募集资金总额2,599,456,347.24元，扣除发行 费用169,031,770.68元（不含增值税）后，募集资金净额为2,430,424,57 ...

国泰海通证券股份有限公司 关于武汉禾元生物科技股份有限公司 使用募集资金置换预先投入募集资金投资项目 及已支付发行费用的自筹资金的核查意见 本次公司首次公开发行募集资金投资项目及募集资金使用计划如下： 单位：万元 1 | 序号 | 项目名称 | 投资总额 | 拟投入募集资金 | | --- | --- | --- | --- | | 1 | 重组人白蛋白产业化基地建设项目 | 190,866.57 | 165,752.73 | | 2 | 新药研发项目 | 79,369.00 | 64,247.27 | | 3 | 补充流动资金 | 10,000.00 | 10,000.00 | | | 合计 | 280,235.57 | 240,000.00 | 公司本次募集资金净额超过上述项目募集资金投资额的部分为超募资金， 超募资金为3,042.46万元。 三、自筹资金预先投入募投项目及已支付发行费用情况及置换安排 （一）筹资金预先投入募投项目情况及置换安排 国泰海通证券股份有限公司（以下简称"保荐人"）作为武汉禾元生物科 技股份有限公司（以下简称"公司"）首次公开发行股票并在科创板上市及持 续督导阶段的保荐人，根据《 ...

武汉禾元生物科技股份有限公司 湖北 武汉 二零二五年十一月 | | | | 第一章 | 总则 | | 3 | | --- | --- | --- | --- | | 第二章 | 经营宗旨和范围 | | 4 | | 第三章 | 股份 | | 5 | | 第四章 | 股东和股东会 | | 9 | | 第五章 | 董事和董事会 | | 24 | | 第六章 | 高级管理人员 | | 36 | | 第七章 | | 财务会计制度、利润分配和审计 | 38 | | 第八章 | 通知和公告 | | 43 | | 第二节 | 公告 | | 44 | | 第九章 | 合并、分立、增资、减资、解散和清算 | 44 | | --- | --- | --- | | 第十章 | 修改章程 | 47 | | 第十一章 | 附则 | 47 | 第一章 总则 第一条 为维护武汉禾元生物科技股份有限公司（以下简称"公司"或者"本公司"）、 股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司 法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）和 其他有关规定，制定本章程。 章 程 第二条 本公司 ...

证券代码：688765 证券简称：禾元生物 公告编号：2025-001 武汉禾元生物科技股份有限公司 关于使用募集资金置换预先投入募投项目及已支付 发行费用的自筹资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 武汉禾元生物科技股份有限公司（以下简称"公司"）于2025年11月21日 召开第四届董事会第十一次会议，审议通过了《关于使用募集资金置换预先投入 募投项目及已支付发行费用的自筹资金的议案》，同意公司使用募集资金人民币 46,955.63万元用于置换预先投入募集资金投资项目（以下简称"募投项目"）的 自筹资金，人民币518.70万元用于置换已支付发行费用的自筹资金。本次募集资 金置换的时间距募集资金到账时间未超过6个月，符合《上市公司募集资金监管 规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等 法律法规、规范性文件的规定。现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意武汉禾元生物科技股份有限 公司首次公开发行股票注册的批复》（ ...

一、现金管理情况概述 （一）现金管理的目的 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等相关规定，为提高资金使用效率，在保证不影 响募集资金投资项目实施、确保募集资金安全的前提下，公司拟对部分暂时闲置 募集资金（含超募资金）进行现金管理，增加资金收益，为公司及股东获取更多 回报。 证券代码：688765 证券简称：禾元生物 公告编号：2025-002 武汉禾元生物科技股份公司 关于使用部分闲置募集资金（含超募资金）进行 现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）现金管理产品品种 公司使用闲置募集资金（含超募资金）购买安全性高、流动性好的保本型产 品（包括但不限于协定性存款、结构性存款、定期存款、通知存款、大额存单等）， 且该等现金管理产品不得用于质押，不得用于以证券投资为目的的投资行为。 （三）资金来源 1、本次现金管理的资金来源为公司 2025 年首次公开发行股票暂时闲置募集 资金（含超募资金）。 2、募集资金的基本情况 根据中国证券监督管 ...

证券代码：688765 证券简称：禾元生物 公告编号：2025-003 武汉禾元生物科技股份有限公司 | 序号 | 修订前 | 修订后 | | --- | --- | --- | | | 第三条 公司于【】年【】月【】日经中 国证券监督管理委员会（以下简称"中国 | 第三条 公司于 2025 年 7 月 16 日经中国 证券监督管理委员会（以下简称"中国证 监会"）同意注册，首次向社会公众发行 | | 1 | 证监会"）同意注册，首次向社会公众发 | 人民币普通股 8,945.1354 万股，于 2025 | | | 行人民币普通股【】万股，于【】在上海 | 年 10 月 28 日在上海证券交易所科创板上 | | | 证券交易所科创板上市。 | | | | | 市。 | | 2 | 第六条 公司注册资本为人民币【】万元。 | 第六条 公司注册资本为人民币 35,750 万 元。 | | 3 | 第二十一条 公司已发行的股份数为【】 | 第二十一条 公司已发行的股份数为 35,7 | | | 万股，均为人民币普通股。 | 50 万股，均为人民币普通股。 | | 4 | 第二百零九条 本章程经股东会决议通过 后生 ...